Late-Breakers to Look Out for at ASCO 2026

Why It Matters

These late‑breakers aim to expand high‑value immuno‑oncology and targeted agents into earlier disease stages, promising larger patient populations and stronger commercial upside. Positive readouts could trigger rapid regulatory approvals and reshape competitive dynamics in oncology.

Key Takeaways

• AstraZeneca tests Imfinzi/tremelimumab combo as first‑line for liver cancer
• Revolution Meds' daraxonrasib shows survival benefit in second‑line pancreatic cancer
• BMS mezigdomide aims to become $1.5 B myeloma blockbuster in phase 3
• J&J's Tecvayli shows death‑risk reduction, targeting earlier multiple myeloma lines
• Trials push immunotherapies and targeted drugs into earlier treatment settings

Pulse Analysis

The American Society of Clinical Oncology’s 2026 meeting continues the industry’s push to bring breakthrough therapies forward in the treatment cascade. Over the past decade, sponsors have increasingly used late‑breaker slots to announce data that move drugs from salvage settings into first‑line or adjuvant indications, a strategy that maximizes market penetration and accelerates revenue. This year’s lineup reflects that trend, with AstraZeneca’s EMERALD‑3 and POTOMAC trials seeking to add Imfinzi‑based regimens to standard liver and bladder cancer protocols, while Revolution Meds’ RASolute 302 aims to turn a pan‑RAS inhibitor into a second‑line lifeline for pancreatic ductal adenocarcinoma, a disease with historically dismal outcomes.

If the data hold up, the financial implications are sizable. Mezigdomide, highlighted in BMS’s SUCCESSOR‑2 phase 3 readout, is projected as a $1.5 billion blockbuster, potentially overtaking legacy IMiDs that are now facing generic erosion. Johnson & Johnson’s PROTEUS and Pfizer’s TALAPRO‑3 could broaden the already lucrative prostate‑cancer market, while J&J’s Tecvayli in the MajesTEC‑9 study may shift its positioning from a late‑line salvage therapy to an earlier relapse‑prevention option, supporting a $5 billion sales ambition. Parallel advances in rare cancers—such as Ideaya/Servier’s OptimUM‑02 for uveal melanoma and Lilly’s SARCO41 for dedifferentiated liposarcoma—demonstrate how niche indications can still drive meaningful revenue when they address unmet needs.

Beyond the headline numbers, these trials underscore a competitive arms race among biotech and big‑pharma players to secure first‑line footholds before peers file similar indications. Regulators are showing willingness to grant expedited reviews for therapies that address high‑mortality cancers, but payers will scrutinize cost‑effectiveness, especially for combination regimens. Investors should monitor the ASCO data closely; positive outcomes could trigger sharp stock moves, while any setbacks may prompt portfolio rebalancing toward alternative pipelines. Ultimately, the late‑breaker slate at ASCO 2026 could set the therapeutic and commercial tone for oncology through 2028.